复宏汉霖(02696)今日盘中股价大涨5.3%,成为市场焦点。
消息面上,复宏汉霖与全球性药企Dr. Reddy's订立许可协议,就其在研抗癌药物HLX15的静脉注射剂型和皮下注射剂型,授予Dr. Reddy's在美国及约42个欧洲国家的开发、生产和商业化权利。根据协议条款,复宏汉霖将获得超过1.316亿美元的收益,其中3300万美元为交易首付款,另有分级特许权使用费。
分析人士认为,此次授权将有望大幅增强复宏汉霖在美欧市场的产品竞争力,长远来看也将为公司带来可观的收益回报。值得一提的是,有基金近日也加码增持复宏汉霖的股份,显示市场对公司未来的发展充满信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.